Distribution Business Sale

RNS Number:4103R
Cytomyx Holdings PLC
19 September 2005


For immediate release                                          19 September 2005



                              CYTOMYX HOLDINGS PLC

                          ("Cytomyx" or "the Company")



                Cytomyx sells distribution business for #900,000

                     to focus on drug discovery technologies



Cytomyx Holdings plc (AIM: CYX), the leading provider of drug discovery products
and services, announced today that it has sold Cambridge BioScience Limited ("
Cambridge BioScience"), its research products distribution business, to Alan
Seeley, a former director of and current shareholder in Cytomyx and the founder
of Cambridge BioScience.



Cambridge BioScience markets research products on behalf of a range of
predominantly US-based manufacturers within the UK and was acquired by Cytomyx
in 2002. In the year ended 30 September 2004, Cambridge BioScience reported a
pre-tax profit of #190,282 on revenues of #2,992,061. As at 31 March 2005, the
date of the last unaudited interim balance sheet, Cambridge BioScience had net
assets of #390,275 and made a pre-tax loss of #61,660 on revenues of #975,427.



Mr Seeley has acquired the business through the purchase of the entire share
capital of Cambridge BioScience. The aggregate consideration paid was #900,000,
satisfied as to #150,000 in cash and the assumption of #750,000 of outstanding
loan notes due to Mr Seeley by Cambridge BioScience from the acquisition of the
business of Cambridge BioScience from him in 2002.



The net proceeds of the disposal will be applied to working capital for the
Company.



The Directors of Cytomyx, having consulted with the Company's nominated adviser,
Corporate Synergy plc, consider that the terms of the disposal are fair and
reasonable so far as shareholders are concerned.





Commenting on the disposal, Mike Kerins, Cytomyx' Chief Executive, said: "The
sale of Cambridge BioScience is consistent with our strategy of building a
leading, technology based, drug discovery solutions provider. We now have a
clear focus on developing technologies that enhance drug discovery productivity.



"Our US operations use human tissue samples to identify the link between genes
and disease to help our clients in the pharmaceutical industry to develop highly
targeted drugs. Our UK business has established itself as the world's leading
developer of ion channel cell lines, which can be used to develop safer drugs by
eliminating those that may fail in clinical development due to toxicity
associated with interactions with ion channels in the heart."







For further information, please contact:

Cytomyx Holdings plc                                 01223 508191
Mike Kerins, Chief Executive

Buchanan Communications                              020 7466 5000
Mark Court/Mary-Jane Johnson






Notes to Editors

About Cytomyx Holdings

Cytomyx Holdings plc is a rapidly growing life science company based in
Cambridge, UK. The Company's primary focus is on developing novel technologies
that assist pharmaceutical and biotechnology companies in their efforts to
develop new treatments more effectively. The company does this by providing
solutions that provide early insights into the likely efficacy and safety
profile of new drugs in development. The Company has two main areas of
expertise: the use of human clinical samples in understanding the linkage
between gene expression and disease and the development of cell-based assays
that are used to support ion channel drug discovery and predict potential
cardiac toxicity in new drugs.  Cytomyx is listed on the AIM market of the
London Stock Exchange (CYX.L). For more information visit
www.cytomyx-holdings.com






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

DISSFDFAMSISESU
Cytomyx (LSE:CYX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024